Published on 31 Jul 2021 on Insider Monkey via Yahoo Finance
The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data. We at Insider Monkey have plowed through 866 13F filings that hedge funds and well-known value investors are required to file by the SEC. The 13F filings show the funds' and investors' portfolio positions as of March 31st. In this article we look at what those investors think of Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL).
Is ZNTL stock a buy? Investors who are in the know were in a bearish mood. The number of long hedge fund bets were trimmed by 1 lately. Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) was in 16 hedge funds' portfolios at the end of the first quarter of 2021. The all time high for this statistic is 17. Our calculations also showed that ZNTL isn't among the 30 most popular stocks among hedge funds (click for Q1 rankings). There were 17 hedge funds in our database with ZNTL holdings at the end of December.
In the financial world there are a large number of tools investors have at their disposal to grade stocks. A pair of the most under-the-radar tools are hedge fund and insider trading indicators. We have shown that, historically, those who follow the top picks of the best fund managers can outperform the broader indices by a solid amount. Insider Monkey's monthly stock picks returned 206.8% since March 2017 and outperformed the S&P 500 ETFs by more than 115 percentage points (see the details here). That's why we believe hedge fund sentiment is a useful indicator that investors should pay attention to.